"Immunogenicity and Safety of Verorab® in a One-week Intradermal Post-exposure Prophylaxis Regimen"

0.1 mL, 4 site 'one week' (4-4-4-0-0) administered intradermally

0.1 mL of vaccine administered intradermally in 4 site 'one week' (4-4-4-0-0) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)

0.1 mL of vaccine administered intradermally in 2-site TRC (2-2-2-0-2) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)